Following an open-label prospective trial in which GS-0976 was observed to obviously reduce liver stiffness and TIMP1 levels in patients with NASH compared to baseline (Lawitz et al., 2018), a randomized controlled trial was conducted in which, consistent with previous studies, 12-week administration of 20 mg GS-0976 significantly reduced liver fat levels and the fibrosis marker TIMP1, as well as lowered liver stiffness measured with the XL probe compared with placebo (Loomba et al., 2018a). The gene discussed is TIMP1; the disease is metabolic dysfunction-associated steatohepatitis.